Global Antibody Drug Conjugates Market US$ 4.

6 Billion by 2021

The global antibody drug conjugates market expected to reach US$ 4.6 billion by 2021, growing at CAGR 30.2% over
the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments.

Antibodydrug conjugates (ADCs), which consist of a mAb chemically linked to a small-molecule therapeutics, are a
niche class of drugs that offer promise, particularly as oncology drugs. ADCs are one of the fastest growing classes
of oncology therapeutics. In the quest for more targeted therapies and potentially more clinically efficacious drugs,
bio/pharmaceutical companies are increasing their research and product development in biologics. Although the
majority of this work is focused on monoclonal antibodies (mAbs) and recombinant proteins, progress is being made
in specialized drug types.

In 2011, US-FDA approved Seattle Genetics/Takedas Adcetris (brentuximab vedotin) for treating Hodgkin lymphoma
and anaplastic large cell lymphoma, followed by, Roches Kadcyla (trastuzumab emtansine) approval in 2013 for the
treatment of breast cancer. Advancements over the past several decades have led to a new generation of ADCs
comprising non-immunogenic mAbs, linkers with balanced stability and highly potent cytotoxic agents. In the recent
years, with the popularity and growth of ADC pipelines, companies have invested in the required supply chains for
raw materials and services to support the highly specialized skills required for ADC containment, development,
manufacturing, and analysis. With a number of ADCs in clinical development, the key question is whether ADCs will
be able to fill a role in biopharmaceutical development. The future of ADCs in the biopharmaceutical market will
ultimately depend on their clinical success.

Visit Antibody Drug Conjugates Market by Marketed Drugs - Adcetris or SGN-35 (Brentuximab vedotin), Kadcyla or
T-DM1 (Trastuzumab emtansine), Pipeline Drugs - Rova-T or SC16LD6.5 (Rovalpituzumab tesirine), CDX011
(Glembatumumab vedotin), Besponsa or CMC-544 (Inotuzumab ozogamicin), IMGN853 (Mirvetuximab
soravtansine), SGNCD33A (Vadastuximab talirine) and Forecast 2017-2021. The global antibody drug conjugates
market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth
trends and forecast (CAGR%, 2017 to 2021). The global antibody drug conjugates market research report is further
segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global antibody drug conjugates market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and
regions or countries.

The report also tracks the major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent developments. Major players operating in the
global antibody drug conjugates market and profiled in this report include AbbVie, Agensys, Inc., Bayer AG, Concortis
Biotherapeutics, F. Hoffman-La Roche Ltd., ImmunoGen, Inc., Immunomedics, Inc., NBE-Therapeutics, Novartis AG,
Pfizer, Sanofi, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.

1. Marketed Drugs
1.1. Adcetris or SGN-35 (Brentuximab vedotin)
1.2. Kadcyla or T-DM1 (Trastuzumab emtansine)

2. Pipeline Drugs
2.1. Rova-T or SC16LD6.5 (Rovalpituzumab tesirine)
2.2. CDX011 (Glembatumumab vedotin)
2.3. Besponsa or CMC-544 (Inotuzumab ozogamicin)
2.4. IMGN853 (Mirvetuximab soravtansine)
2.5. SGNCD33A (Vadastuximab talirine)

3. Geography
 3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC
3.5. Rest of the World

4. Company Profiles
4.1. AbbVie
4.2. Agensys, Inc.
4.3. Bayer AG
4.4. Concortis Biotherapeutics
4.5. F. Hoffman-La Roche Ltd.
4.6. ImmunoGen, Inc.
4.7. Immunomedics, Inc.
4.8. NBE-Therapeutics
4.9. Novartis AG
4.10. Pfizer
4.11. Sanofi
4.12. Seattle Genetics, Inc.
4.13. Takeda Pharmaceutical Company Limited

To request Table of Contents and Sample Pages of this report visit:

https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting
grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client
assignments targeted at clients specific business objectives, information needs, time frame and budget. Please
contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com